Astellas Pharma Inc: Arthritis, Rheumatoid trials

The registry lists 29 Arthritis, Rheumatoid studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 7Phase 3 9Phase 4 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedNCT02308163Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedNCT02305849Phase 3Results posted
• A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedNCT01638013Phase 3Results posted
• Efficacy Confirmation Study of CDP870 in Early Rheumatoid ArthritisCompletedNCT01451203Phase 3Results posted
• Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) PatientsCompletedNCT00851318Phase 3Results posted
• Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) PatientsCompletedNCT00850343Phase 3Results posted
• Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisCompletedNCT03971253
• A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)CompletedNCT03737708Phase 4
• A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)CompletedNCT03660059Phase 3
• A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on MethotrexateCompletedNCT03257852Phase 2
• A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking MethotrexateCompletedNCT02884635Phase 2
• A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT02867306Phase 1
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on MethotrexateCompletedNCT02698657Phase 1
• Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870CompletedNCT02586246Phase 3
• A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on MethotrexateCompletedNCT02171143Phase 1
• A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on MethotrexateCompletedNCT02052375Phase 1
• Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis PatientsCompletedNCT01870908
• A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT01754805Phase 1
• A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyCompletedNCT01711814Phase 2
• A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis SubjectsCompletedNCT01649999Phase 2
• A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisCompletedNCT01565655Phase 2
• A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateCompletedNCT01554696Phase 2
• A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)CompletedNCT01511003Phase 4
• A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating AbataceptCompletedNCT01339481
• A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to MethotrexateCompletedNCT01224418Phase 4
• Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to MethotrexateCompletedNCT01224041Phase 4
• Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid ArthritisCompletedNCT00411424Phase 1/2
• A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA PatientsCompletedNCT00319917Phase 4
• Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid ArthritisCompletedNCT00036153Phase 3